HOME > BUSINESS
BUSINESS
- Baxalta Sues Chugai over Hemophilia A Drug Patent
May 12, 2016
- Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
May 12, 2016
- Astellas Logs Record Earnings on Bullish Xtandi in FY2015
May 12, 2016
- Entyvio on Track to Rake in US$2 Billion in FY2018, Ninlaro Eyed as Next Big Seller
May 11, 2016
- Takeda Drops Diabetic Nephropathy Drug amid Change in R&D Strategy
May 11, 2016
- Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
May 11, 2016
- Meiji Seika Pharma Jettisons BPH Treatment
May 11, 2016
- AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
May 11, 2016
- Taiho Establishes Venture Capital Unit in US to Invest in Field of Oncology
May 11, 2016
- Daiichi Sankyo Enters License Agreement with UK Company for Cell Therapy
May 11, 2016
- Aspen Japan Files Requests for Reimbursement Listing of Paxil, Valtrex AGs
May 10, 2016
- Takeda Gets US$38 Million Grant from Gates Foundation for Polio Vaccine Development
May 10, 2016
- Thorsten Poehl Takes Helm of Boehringer Japan
May 10, 2016
- D. Western Therapeutics Acquires Exclusive License to Corneal Endothelial Therapeutics from Doshisha Univ.
May 10, 2016
- Transfer of Vaccine, Blood Biz under Negotiation, All Directors to Exit in June: Kaketsuken
May 9, 2016
- Ex-Ranbaxy Shareholders Ordered to Pay 56 Billion Yen to Daiichi Sankyo
May 9, 2016
- Shingo Iwamoto to Lead Aspen Japan
May 9, 2016
- Halaven Approved for Advanced Liposarcoma in Europe: Eisai
May 9, 2016
- Brintellix Renamed Trintellix to Curb Name Confusion in US
May 9, 2016
- Ono Ups FY2015 Earnings Forecast on Brisk Opdivo Sales
May 9, 2016
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
